- Report
- May 2025
- 196 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- August 2024
- 136 Pages
Global
From €2632EUR$2,999USD£2,277GBP
- Report
- July 2025
- 372 Pages
Global
From €5134EUR$5,850USD£4,442GBP
- Report
- May 2025
- 195 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- May 2025
- 196 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- May 2025
- 191 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- May 2025
- 186 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- February 2025
- 200 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- February 2025
- 200 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- April 2025
- 250 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- July 2025
- 213 Pages
Global
From €5134EUR$5,850USD£4,442GBP
- Report
- July 2025
- 158 Pages
Global
From €5134EUR$5,850USD£4,442GBP
- Report
- March 2025
- 180 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- January 2025
- 183 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- September 2024
- 187 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- June 2025
- 150 Pages
Global
From €3379EUR$3,850USD£2,923GBP
- Report
- June 2025
- 400 Pages
Global
From €4343EUR$4,949USD£3,758GBP
- Report
- January 2025
- 210 Pages
Global
From €4384EUR$4,995USD£3,793GBP
- Report
- July 2024
- 158 Pages
Global
From €3730EUR$4,250USD£3,227GBP
- Report
- December 2024
United States
From €1624EUR$1,850USD£1,405GBP

The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more